Biotech, Inc. Fortress Net Worth

The estimated Net Worth of Biotech, Inc. Fortress is at least $274 Thousand dollars as of 8 September 2023. Biotech Fortress owns over 418,410 units of Mustang Bio Inc stock worth over $273,996 and over the last 8 years Biotech sold MBIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Biotech Fortress MBIO stock SEC Form 4 insiders trading

Biotech has made over 1 trades of the Mustang Bio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Biotech bought 418,410 units of MBIO stock worth $301,255 on 8 September 2023.

The largest trade Biotech's ever made was buying 418,410 units of Mustang Bio Inc stock on 8 September 2023 worth over $301,255. On average, Biotech trades about 27,894 units every 0 days since 2017. As of 8 September 2023 Biotech still owns at least 1,032,390 units of Mustang Bio Inc stock.

You can see the complete history of Biotech Fortress stock trades at the bottom of the page.

What's Biotech Fortress's mailing address?

Biotech's mailing address filed with the SEC is 1111 KANE CONCOURSE SUITE 301, , BAY HARBOR ISLANDS, FL, 33154.

Insiders trading at Mustang Bio Inc

Over the last 7 years, insiders at Mustang Bio Inc have traded over $122,072 worth of Mustang Bio Inc stock and bought 951,208 units worth $2,853,591 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, and Manuel Md Litchman. On average, Mustang Bio Inc executives and independent directors trade stock every 89 days with the average trade being worth of $15,504. The most recent stock trade was executed by Manuel Md Litchman on 18 March 2022, trading 10,000 units of MBIO stock currently worth $6,300.

What does Mustang Bio Inc do?

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.

Complete history of Biotech Fortress stock trades at Checkpoint Therapeutics Inc, Avenue Therapeutics Inc, and Mustang Bio Inc

Mustang Bio Inc executives and stock owners

Mustang Bio Inc executives and other stock owners filed with the SEC include:

• Dr. Manuel Litchman,
  Pres, CEO & Director
• Manuel Litchman,
  President, Chief Executive Officer, Director
• Brian Achenbach,
  Senior Vice President - Finance, Corporate Controller
• Brian K. Achenbach M.B.A.,
  Sr. VP of Fin. & Corp. Controller
• Adam Chill,
  Independent Director
• Michael Weiss,
  Executive Chairman of the Board
• Michael Zelefsky,
  Independent Director
• Neil Herskowitz,
  Independent Director
• Lindsay Rosenwald,
  Director
• Michael S. Weiss Esq.,
  Exec. Chairman
• Robyn M. Hunter,
  Corp. Sec.
• Dr. Bruce Dezube M.D.,
  Sr. VP & Head of Clinical Devel.
• Scott Smith M.B.A.,
  Exec. Director and Head of Alliance & Program Management
• Lynn E. Bayless,
  Head of Regulatory Affairs
• Debra Manning SPHR,
  VP of HR
• Matthew Wein J.D.,
  VP & Gen. Counsel
• Dr. Knut Niss,
  Chief Technology Officer
• Biotech, Inc. Fortress,
  10% owner